Glaukos Announces Participation in Piper Jaffray Healthcare Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 2:30 p.m. EST in New York City.
A live audio webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com and will be archived for 90 days.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
Contacts
Chris Lewis
Director, Investor Relations, Corporate Strategy & Development
(949) 481-0510
clewis@glaukos.com
